M&As this week: Zhejiang Hisoar Pharmaceutical, tella


Chinese pharmaceutical company Zhejiang Hisoar Pharmaceutical plans to divest a 16.1% stake in a biotechnology company.

The sale is planned to be made to limited partnerships and individuals for CNY144m ($21.8m).

Regenerative and cell medicines developer tella has divested a 44.4% stake in a cell processing facilities consolidated subsidiary.

"Regenerative and cell medicines developer tella has divested a 44.4% stake in a cell processing facilities consolidated subsidiary."

tella has received CNY110m ($0.98m) as consideration from the sale.

Both entities involved in the transaction are based in Japan.